PODD:NSD-Insulet Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 192.56

Change

0.00 (0.00)%

Market Cap

USD 11.90B

Volume

0.30M

Average Target Price

USD 159.55 (-17.15%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, the United Kingdom, the Netherlands, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-01-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

N/A

USD21.28B 51.83 36.47
ABMD Abiomed, Inc

N/A

USD8.26B 38.20 29.52
BRKR Bruker Corporation

N/A

USD8.07B 40.00 22.74
SDC SmileDirectClub, Inc

N/A

USD5.00B N/A -2.70
IART Integra LifeSciences Holdings ..

N/A

USD4.74B 80.48 16.73
TNDM Tandem Diabetes Care, Inc

N/A

USD4.08B N/A -318.20
NUVA NuVasive, Inc

N/A

USD4.01B 85.76 18.98
WMGI Wright Medical Group N.V

N/A

USD3.85B N/A 46.02
LIVN LivaNova PLC

N/A

USD3.44B 77.40 34.94
CNMD CONMED Corporation

N/A

USD3.06B 107.36 23.68

ETFs Containing PODD

Symbol Name Weight Mer Price(Change) Market Cap
SLIM The Obesity ETF 4.77 % 0.35 %

N/A

USD0.01B
PTH Invesco DWA Healthcare Mo.. 3.24 % 0.60 %

N/A

USD0.18B
SID:CA CI First Asset U.S. Trend.. 2.50 % 0.95 %

N/A

USD0.03B
FHH:CA FT AlphaDEX U.S. Health C.. 2.23 % 0.70 %

N/A

USD0.01B
FCVT First Trust SSI Strategic.. 1.92 % 0.95 %

N/A

USD0.22B
VBK Vanguard Small-Cap Growth.. 0.61 % 0.07 %

N/A

USD25.93B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.48% 67% D+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.48% 67% D+ 85% B
Trailing 12 Months  
Capital Gain 145.46% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 145.46% 92% A- 95% A
Trailing 5 Years  
Capital Gain 515.21% 98% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 515.21% 98% A+ 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 46.44% 81% B- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.44% 81% B- 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 38.43% 60% D- 33% F
Risk Adjusted Return 120.85% 100% A+ 95% A
Market Capitalization 11.90B 99% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 746.36 7% F 1% F
Price/Book Ratio 79.02 3% F 1% F
Price / Cash Flow Ratio 331.61 4% F 1% F
EV/EBITDA 146.62 1% F 2% F
Management Effectiveness  
Return on Equity 9.48% 84% B 69% D+
Return on Invested Capital 3.64% 62% D- 48% F
Return on Assets 3.52% 79% C+ 74% C
Debt to Equity Ratio 279.10% 9% F 6% F
Technical Ratios  
Short Ratio 8.38 14% F 19% F
Short Percent 10.36% 36% F 29% F
Beta 0.98 45% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.